Clinical Trial Update: Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial of atrasentan in men with non-metastatic, hormone-refractory prostate cancer completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Atrasentan (atrasentan)

Snippet

Sponsor: Abbott | Conditions: Prostatic Neoplasms | Phase 3 | Status: COMPLETED